Loading...
•
Jun 30, 2022
Leap Therapeutics Q2 2022 Earnings Report
Leap Therapeutics reported financial results for the second quarter ended June 30, 2022.
Key Takeaways
Leap Therapeutics reported a net loss of $17.0 million for the second quarter of 2022, compared to a net loss of $9.5 million for the same period in 2021. Research and development expenses were $14.0 million, compared to $7.2 million for the three months ended June 30, 2021. Cash and cash equivalents totaled $90.9 million at June 30, 2022.
Initiated a randomized controlled clinical trial in combination with BeiGene’s tislelizumab and chemotherapy in first-line G/GEJ cancer patients.
Results from Part A and B of the DisTinGuish study have been compelling.
Initiated a company-sponsored study in second-line colorectal cancer patients.
Supporting an investigator-initiated study with Merck’s anti-PD-1 antibody pembrolizumab in endometrial cancer patients.